What is RenalSense?
RenalSense operates at the intersection of medical device engineering and clinical data analytics. The company is primarily recognized for its flagship product, Clarity RMS, which facilitates the continuous and automated monitoring of urine flow. By providing clinicians with real-time data, the system significantly enhances patient care protocols and optimizes ICU economics. The firm's market position is defined by its commitment to improving peri-operative outcomes through high-fidelity diagnostic tools that address the complexities of renal function management in high-acuity settings.
How much funding has RenalSense raised?
RenalSense has raised a total of $14M across 1 funding round:
Series A
$14M
Series A (2021): $14M with participation from BlueRed Partners
Key Investors in RenalSense
BlueRed Partners
BlueRed Partners is a Singapore-based investment fund that focuses on disruptive, early, and growth-stage technology companies from Israel, targeting Asian markets for its investments.
What's next for RenalSense?
With the infusion of this recent capital, RenalSense is well-positioned to accelerate the development of its next-generation product pipeline. The strategic roadmap focuses on integrating additional real-time parameters into its existing diagnostic framework, thereby expanding its utility in both ICU and peri-operative environments. By leveraging this financial backing, the company aims to solidify its footprint in the medical technology sector, focusing on long-term value creation through clinical efficacy and the systematic expansion of its diagnostic capabilities to meet the evolving demands of modern healthcare providers.
See full RenalSense company page
